Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 325,272 |
|
|||||
| News | - | ||||||
| Day High | 4.15 | Low High |
|||||
| Day Low | 3.88 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sagiment Biosciences Inc | SGMT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.14 | 3.57% | 4.06 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.00 | 3.88 | 4.15 | 4.06 | 3.92 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,561 | 325,272 | $ 4.03 | $ 1,312,153 | - | 2.13 - 20.71 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:40:01 | 1 | $ 4.07 | USD |
Sagiment Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 87M | 21.38M | - | 2M | -27.88M | -1.30 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sagiment Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SGMT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.91 | 4.31 | 3.83 | 4.09 | 308,257 | 0.15 | 3.84% |
| 1 Month | 5.63 | 5.825 | 3.83 | 4.84 | 432,414 | -1.57 | -27.89% |
| 3 Months | 10.35 | 11.03 | 3.83 | 6.02 | 1,029,570 | -6.29 | -60.77% |
| 6 Months | 4.16 | 20.71 | 2.13 | 10.42 | 973,690 | -0.10 | -2.40% |
| 1 Year | 15.50 | 20.71 | 2.13 | 10.54 | 667,212 | -11.44 | -73.81% |
| 3 Years | 15.50 | 20.71 | 2.13 | 10.54 | 667,212 | -11.44 | -73.81% |
| 5 Years | 15.50 | 20.71 | 2.13 | 10.54 | 667,212 | -11.44 | -73.81% |
Sagiment Biosciences Description
| Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. |
